ArticleFrontiers in oncology2026
Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome-a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal adenoid cystic carcinoma (ACC) is an exceptionally rare malignancy, and its association with second primary malignancies (SPMs) remains poorly characterized. This report presents the first documented case of metachronous esophageal squamous cell carcinoma (SCC) developing outside the radiation field following curative treatment of esophageal ACC. Case presentation: A 58-year-old male with a substantial smoking history presented with dysphagia in 2022. Diagnostic evaluation confirmed primary esophageal ACC (pT2N0M0, Stage IIA), exhibiting perineural invasion and a high proliferative index (Ki-67 80%). The patient underwent surgical resection followed by adjuvant radiotherapy (50 Gy/25 fractions) to the tumor bed. Postoperative radiotherapy was well tolerated, with only Grade 1 esophagitis and fatigue observed. Sixteen months later, during routine surveillance, a new cervical esophageal lesion was detected 5 cm proximal to the previous anastomotic site, well beyond the prior radiation field. Histopathological examination identified poorly differentiated SCC with distinct immunohistochemical characteristics (P40 diffuse+, Ki-67 30%). Complete remission was achieved following definitive chemoradiotherapy (60 Gy/28 fractions to PGTV, 54 Gy/28 fractions to PTV with concurrent S-1). At the most recent follow-up in March 2026, the patient remained disease-free. Conclusion: This case illustrates that SPMs may arise outside irradiated regions after ACC treatment, excluding radiation-induced carcinogenesis. The findings emphasize the necessity of comprehensive endoscopic surveillance of the entire esophagus for early detection of secondary primaries in patients treated for esophageal ACC. Furthermore, the favorable therapeutic response demonstrates that curative-intent management remains feasible for metachronous malignancies when identified at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.